27076-16-0 Usage
General Description
5-ethoxy-2-nitroaniline is a chemical compound that consists of a nitro group, an aniline group, and an ethoxy group attached to a benzene ring. It is commonly used as an intermediate in the production of dyes and pigments. 5-ethoxy-2-nitroaniline is also used as a reagent in organic synthesis and as an analytical reagent in the determination of various substances. Due to its chemical properties, it is important to handle 5-ethoxy-2-nitroaniline with caution, as it can be toxic and harmful if not used properly. Additionally, it is important to store and transport this compound in accordance with safety regulations to prevent potential accidents or harm to individuals.
Check Digit Verification of cas no
The CAS Registry Mumber 27076-16-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,7,0,7 and 6 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 27076-16:
(7*2)+(6*7)+(5*0)+(4*7)+(3*6)+(2*1)+(1*6)=110
110 % 10 = 0
So 27076-16-0 is a valid CAS Registry Number.
27076-16-0Relevant articles and documents
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: The role of extravascular transport
Hay, Michael P.,Hicks, Kevin O.,Pruijn, Frederik B.,Pchalek, Karin,Siim, Bronwyn G.,Wilson, William R.,Denny, William A.
, p. 6392 - 6404 (2007)
Pharmacokinetic/pharmacodynamic (PK/PD) modeling has shown the antitumor activity of tirapazamine (TPZ), a bioreductive hypoxia-selective cytotoxin, to be limited by poor penetration through hypoxic tumor tissue. We have prepared a series of 1,2,4-benzotr
NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES
-
Page/Page column 40, (2010/02/13)
The present invention provides a simplified set of characteristics that can be used to select 1,2,4 benzotriazine 1,4 dioxide compounds (TPZ analogues) with therapeutic activity against hypoxic cells in human tumour xenografts, and to further provide a no
